ETRA Electra Therapeutics, Inc. Common stock
XNASStock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.

- Industry (SIC)
- BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) (2836) · industry map
- Exchange
- XNAS
- Market Cap
- $0.5B
- List Date
- 2026-09-18
- CIK
- 0002088082
- Homepage
- https://www.electra-therapeutics.com
Electra Therapeutics Inc is a late clinical-stage biopharmaceutical company focused on pioneering a new class of precision medicines for the treatment of immune-mediated diseases and cancer.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Click Frenzy-Pro™ for an AI analysis of this ticker.
Analysis includes technical indicators, news sentiment, risk assessment, and specific price levels to watch.
ETRA Options Activity & IV Rank
Each spread is ranked by a composite score built in three stages. Full documentation →
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Enter a ticker to render the implied volatility surface.
Enter a ticker to render the implied volatility smile.
ETRA Institutional Ownership (13F)
Latest filings — 2026-09-30Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
| # | Filer | Notional Value | % of Total | Period |
|---|
| # | Filer | Notional Value | % of Total | Period |
|---|
ETRA Insider Trading (Form 4)
Latest: 2026-09-23| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-09-23 | OrbiMed Capital GP VII LLC | Director | Mixed | +20,655,510 | $15.00 | $60.00M | EDGAR |
| 2026-09-23 | Carl L Gordon | Director | Mixed | +6,885,170 | $15.00 | $20.00M | EDGAR |
| 2026-09-21 | Quehuong (Kathy) Dong | President & CEO | Conv (C) | +455,484 | — | EDGAR | |
| 2026-09-21 | Gary S. Koe | Chief Technical Officer | Conv (C) | +63,656 | — | EDGAR | |
| 2026-09-21 | Nancy Stagliano | Director | Conv (C) | +255,635 | — | EDGAR | |
| 2026-09-21 | Graham Parry | Chief Scientific Officer | Conv (C) | +85,504 | — | EDGAR |
ETRA Insider Holdings
6 insiders| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | OrbiMed Capital GP VII LLC | Director | 3,090,244 | — | $60.00M | 1 | 2026-09-23 |
| 2 | Carl L Gordon | Director | 2,002,310 | — | $20.00M | 1 | 2026-09-23 |
| 3 | Quehuong (Kathy) Dong | President & CEO | 455,484 | — | $0 | 1 | 2026-09-21 |
| 4 | Nancy Stagliano | Director | 255,635 | — | $0 | 1 | 2026-09-21 |
| 5 | Graham Parry | Chief Scientific Officer | 85,504 | — | $0 | 1 | 2026-09-21 |
| 6 | Gary S. Koe | Chief Technical Officer | 63,656 | — | $0 | 1 | 2026-09-21 |
ETRA Board & Officers
As of SEC filings through Sep 23, 2026Directors 7
- Carl L Gordon · since Sep 18, 2026
- Matthew K Fust · since Sep 18, 2026
- Nancy Stagliano · since Sep 18, 2026
- OrbiMed Capital GP VII LLC (entity) · since Sep 18, 2026
- OrbiMed Genesis GP LLC (entity) · since Sep 18, 2026
- Orbimed Advisors LLC (entity) · since Sep 18, 2026
- Quehuong (Kathy) Dong · since Sep 18, 2026
Officers 6
- Quehuong (Kathy) Dong · President & CEO · since Sep 18, 2026
- Christopher William Clark · Chief Financial Officer · since Sep 18, 2026
- Gary S. Koe · Chief Technical Officer · since Sep 18, 2026
- Graham Parry · Chief Scientific Officer · listed since Sep 2026
- Kim-Hien Dao · Chief Medical Officer · since Sep 18, 2026
- David J. Tucker · Principal Accounting Officer · since Sep 18, 2026
10% owners 8
- Carl L Gordon · listed since Sep 2026
- OrbiMed Capital GP VII LLC (entity) · listed since Sep 2026
- OrbiMed Genesis GP LLC (entity) · listed since Sep 2026
- Orbimed Advisors LLC (entity) · listed since Sep 2026
- Westlake BioPartners Fund I, L.P. (entity) · since Sep 21, 2026
- Westlake BioPartners Fund II, L.P. (entity) · since Sep 21, 2026
- Westlake BioPartners GP I, LLC (entity) · since Sep 21, 2026
- Westlake BioPartners GP II, LLC (entity) · since Sep 21, 2026
Changes in the last 10 years (22)
| Sep 23, 2026 | Orbimed Advisors LLC first listed as a 10% owner in an SEC filing |
| Sep 23, 2026 | OrbiMed Genesis GP LLC first listed as a 10% owner in an SEC filing |
| Sep 23, 2026 | OrbiMed Capital GP VII LLC first listed as a 10% owner in an SEC filing |
| Sep 23, 2026 | Carl L Gordon first listed as a 10% owner in an SEC filing |
| Sep 21, 2026 | Westlake BioPartners GP II, LLC became a 10% owner |
| Sep 21, 2026 | Westlake BioPartners GP I, LLC became a 10% owner |
| Sep 21, 2026 | Westlake BioPartners Fund II, L.P. became a 10% owner |
| Sep 21, 2026 | Westlake BioPartners Fund I, L.P. became a 10% owner |
| Sep 18, 2026 | Quehuong (Kathy) Dong became a director |
| Sep 18, 2026 | Quehuong (Kathy) Dong became President & CEO |
| Sep 18, 2026 | Orbimed Advisors LLC became a director |
| Sep 18, 2026 | OrbiMed Genesis GP LLC became a director |
| Sep 18, 2026 | OrbiMed Capital GP VII LLC became a director |
| Sep 18, 2026 | Nancy Stagliano became a director |
| Sep 18, 2026 | Matthew K Fust became a director |
| Sep 18, 2026 | Kim-Hien Dao became Chief Medical Officer |
| Sep 18, 2026 | Graham Parry listed as Chief Scientific Officer (previously Principal Accounting Officer) in SEC filings |
| Sep 18, 2026 | Graham Parry became Principal Accounting Officer |
| Sep 18, 2026 | Gary S. Koe became Chief Technical Officer |
| Sep 18, 2026 | David J. Tucker became Principal Accounting Officer |
| Sep 18, 2026 | Christopher William Clark became Chief Financial Officer |
| Sep 18, 2026 | Carl L Gordon became a director |
- Prev
- 1
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|---|---|---|---|---|---|
| 1 | VTI Vanguard Morningstar Total Stock Market ETF | Vanguard | 0.00% | $1.5M | — | 2026-09-30 |
| 2 | VXF Vanguard Extended Market ETF | Vanguard | 0.00% | $598,635 | — | 2026-09-30 |
| 3 | VTWO Vanguard Russell 2000 ETF | Vanguard | 0.00% | $178,031 | — | 2026-09-30 |
| 4 | VTWG Vanguard Russell 2000 Growth ETF | Vanguard | 0.00% | $17,944 | — | 2026-09-30 |
| 5 | VTWV Vanguard Russell 2000 Value ETF | Vanguard | 0.00% | $6,311 | — | 2026-09-30 |
| 6 | VTHR Vanguard Russell 3000 ETF | Vanguard | 0.00% | $2,520 | — | 2026-09-30 |
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.